Brazilian regulatory agency (ANVISA) inaugurates discussion on cannabis for medicinal and scientific purposes -

June 12, 2019

ANVISA’s Board of Directors approved the proposal to open two Public Consultations to regulate:

(i) the cultivation of the cannabis spp. for medical and scientific purposes; and

(ii) a specific procedure for registration and monitoring of medicines based on Cannabis spp., its derivatives, and synthetic analogs.

For further information, click below to access our full newsletter.

Last related news

November 14, 2022

On November 8, 2022, the Brazilian Data Protection Authority (“Authority”) published its 2023-2024 Regulatory Agenda (“Current Agenda”), establishing high-priority topics over the … Brazilian Data Protection Authority publishes its 2023-2024 Regulatory Agenda

November 10, 2022

On October 19, 2022, the Brazilian House of Representatives approved Bill No. 2.796/2021 that creates a legal framework for the Brazilian gaming … Bill creates Legal Framework for the Electronic Games Industry in Brazil

October 20, 2022

The Federal Council of Medicine (CFM) published, on 10/14/2022, CFM Resolution No. 2,324/22, which authorizes the use of cannabidiol (CBD) for treatment … CFM updates its Resolution on cannabidiol prescription and use